

CONTRACTOR OF THE PARTY OF THE

1

R

# Care for appetite foundation

W 8285 1 854

Anshika Anshika Miss. 10598364E 1097327 antero-posterior Factory3. 20-May-22. 10:37 AM.
CARDIO THORACIC & NEURO SCIENCES CENTRE(AliMS DELHI)



# MLPASure: SMA Test Report

#### PATIENT INFORMATION

Sample Type Name Kundan V 27/08/2019 Collection Date 13/10/2006 Date of Birth 08:40 Collection Time (Hrs.) Male Gender 28/08/2019 Receipt Date 12 years 10 months Age (years) 09/09/2019

Patient ID : Report Date : 09/09/ Sample ID : BECGI195777 Reporting Time (Hrs.) : 08:00

Test Code : MLP-SMA-ECGI Clinician Name : Dr. A A Mathew
Test Method : MLPA Hospital Name : Sagar Hospital, Bengaluru

#### RESULTS

SMN1: Zero copies of exon 7 and exon 8 in SMN1 gene identified. Homozygous deletion on exon 7 and exon 8 in SMN1 gene was observed. This indicates that individual is likely to be affected of SMA

SMN2: Greater than four copies of exon 7 and 8 in SMN2 gene identified. Ambiguious duplication in exon 7 and exon 8 of SMN2 gene observed.

#### INTERPRETATION

A sample from this individual was referred to our laboratory for molecular testing for Spinal Muscular Atrophy (SMA). SMA is a group of autosomal recessive neuromuscular disorders characterized by degeneration of the anterior horn cells of the spinal cord, leading to symmetrical muscle weakness and atrophy.

SMN Gene	Exons	Dosage quotient"	Copy Number Status	Deletions / Duplications
SMN1	FV7	0.0	u coples 0	Homozygous detetion
	EXB	0.0		Homozygous deletion
SMN Gene	Exons	Dosage quotient*	Copy Number Status	Deletions / Duplications
SMN2	Ex 7	5.56	>4 copic s	Ambiguous duplication
	FT. 0	0.24		Ambiguous duplication

MLPA probe ratio-Dosage quotient (DC) — Homozygous wild type: 0.2 < DC=1.20, Homozygous deletion: DQ=0.0, Heterozygous deletion: 0.40<DQ<0.65, Heterozygous duplication: DQ=2.20

Comment: The above mentioned result must be interpreted in the context of the individual's clinical and biochemical profile. Genetic counseling is advised.

Note: The SALSA MLPA probemix P060-B2 SMA detects deletions/duplications in specific regions in SMN1 and SMN2 genes only. Smaller deletions, duplications and point mutations in these genes or elsewhere in the genome will not be detected by this technique.

#### **METHODOLOGY**

Mutational analysis by multiplex ligation probe dependent amplification (MLPA, MRC Holland) using SALSA MLPA probe mix P060-B2 SMA for SMN1 and SMN2 gene. Analysis was done by Coffalyser (designed by MRC-Holland). Note: Despite all precautions, the error rate in molecular tests can be 1-2%. We strongly recommend that this report should be correlated with clinical information.

#### REFERENCE

Prior TW, Nagan N, Sugarman EA, Batish SD, Braastad C, Technical standards and guidelines for spinal muscular atrophy testing. Genet Med. 2011 Jul;13(7):686-94. doi: 10.1097/GIM.0b013e318220d523. PubMed PMID: 21673580.

Abdul Mueed Bidchol, PhD Clinical Reporting Manager Sam Balu, PhD Asst. Laboratory Director

### **Eurofins Clinical Genetics India Private Limited**

540/1, Doddanakundi Industrial Area 2, Hoodi, Whitefield, Bengaluru 560048, Karnataka, India.

Tel: +91 80 67223200, Customer care: +91 8884611339,

Genetic Counselor: +91 8884124543, Email: Clinicalgenetics@eurofins.com, Website: www.eurofinsclinicalgenetics.co.in, CIN: U74900KA2015FTC084665







Ver. No.: 02/2019

## NATIONAL INSTITUTE OF MENTAL HEALTH & NEURO SCIENCES

P B 2900, Hosur Road, Bangalore-560029 DEPARTMENT OF NEUROPATHOLOGY

Phone: 080-26995130 Email: neuropathology a nimhans.kar.nic.in REPORT OF HISTOPATHOLOGICAL EXAMINATION

Name: Master Kundan

Age:4yrs

Sex:M

Neuropath No.: X-2579 /11

ID No.

Ref. By: Drs. Krishna Prasad, Suguna

Hospital, Blore

Nature of Specimen:

Received muscle biopsy (irregularly sectioned), appearing fibrous with intramuscular septrum(1.5x1x0.8cm)

Histopathology report:

Paraffin and cryosections from skeletal muscle tissue shows preserved architecture, moderate perimysial fibrosis and adipose tissue infiltration. Fascicular architecture is partly effaced. Fascicles comprise hypertrophic and atrophic fibers in groups and an admixture of hypertrophic and atrophic fibers in a few. Enzyme stains reveal type I fiber hypertrophy and grouping and group atrophy of type II fibers.

Impres Care for appetite
Spinal muscular atrophy-Type II (vastus lateralis per la lateralis

Dr.N.Gayathri
Addl.Professor
16/08/11

foundation

# **Bangalore Baptist Hospital**

Quality with Compassion Since 1973



Name: Kundan Veluru

DOB: 13/10/06

Age: 15 years and 1 month

Weight: 37.8 kgs

10/11/21 Bengaluru

RISDIPLAM (EVRYSDI) 60 mgs in each vial- to be mixed with 79 ml of sterile water to make up to a volume of 80 ml. So the concentration is 0.75mg in each ml.

Dose: To take 5 mgs once daily = 6.6 ml once daily x 6 months and continue.

Dr. Ann Agnes Mathew

MRCPCH, FRCPCH, Fellow Paediatric Neurology, Fellow Paediatric Neuro Vascular Diseases, Fellow Paediatric Neuromuscular Diseases allow Paediatric Epilepsy

onsulant Pagalatric Neurologist MC No. 61773

Dr. Ann Agnes Mathew, KMC No: 61273

MRCPCH, FRCPCH, Fellow Paediatric Neurology,

Fellow Paediatric Epilepsy, Fellow Paediatric Stroke.

Fellow Paediatric Neuroniuscular Discases: Consultant Paediatric Neurologist

Bangalore Baptist Hospital

Bangalore Baptist Hospital

Bellary Road, Hebbal, Bangalore - 560024.







